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ABSTRACT
PURPOSE: There is evidence that female sex hormones impact caffeine metabolism,
with decreased CYP1A2 activity and diminished caffeine clearance in women with
higher estrogen levels. Therefore, the objectives of this project were to determine
the effects of oral contraceptives and menstrual cycle on the benefits of caffeine
supplementation for cycling performance. METHODS: Sixteen recreationally trained
female cyclists, oral contraceptive steroid (OCS) users (n=8, age = 21.4 ± 1.4 years,
height = 168.4 ± 3.6 cm, weight = 63.6 ± 7.2kg, VO2max = 48.0 ± 4.0 mlkg-1min-1)
and non-users (n=8, age = 20.9 ± 2.1 years, height = 161.0 ± 7.7 cm, weight = 59.5 ±
9.2 kg, VO2max = 50.9 ± 7.8 mlkg-1min-1), completed four separate computersimulated 3-km cycling time trials (TT). Subjects ingested either 6mg/kg of caffeine
or a placebo capsule one hour prior to each trial. Magnitude based inferences were
used to evaluate treatment differences. RESULTS: Caffeine enhanced 3-km TT
performance (compared to placebo) in early and late phases of the menstrual cycle
for OCS users ‘possibly’ and ‘very likely’ by 1.6 ± 2.1%, 2.7 ± 1.4% and non-users
‘likely’ by 2.6 ± 2.3%, 2.1 ± 2.2% respectively. All other comparisons for OCS users
and non-users were ‘unclear’. CONCLUSIONS: Caffeine supplementation improved
3-km TT finishing time and average power output in follicular and luteal phases of
the menstrual cycle, with unclear differences between the phases for both OCS users
and non-users. This indicates that menstrual status is not a significant source of
variability on the ergogenic effect of caffeine supplementation on cycling
performance.
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Chapter One
Introduction
Caffeine (1,3,7-trimethylxanthine) is often consumed for its stimulating effects and
ability to improve physical performance (6). There is good evidence that caffeine
supplementation can enhance physical performance ranging from peak strength to
endurance performance (4–6, 11, 16, 21, 23, 55, 57, 61, 62). Early research
suggested that the ergogenic effect of caffeine on aerobic exercise stem from
adrenaline-augmented free-fatty acid oxidation and glycogen sparing (13). Recently,
the physiological responses to exercise altered by caffeine are suggested to be
through stimulation of the central nervous system mediated by antagonizing
adenosine receptor sites (51), which increases motor-unit recruitment in large
muscle groups (5, 60) and reduces the rate of perceived exertion during endurance
exercise (5, 6, 13, 17). It is also accepted that caffeine binds to adenosine receptors
limiting the relaxation of smooth muscles and vasodilation in the visceral organs in
order to increase blood to the muscles (19).
The optimal caffeine dose for performance benefits is between 3 and 6 mg of
caffeine per kilogram of body mass (14, 21, 23, 57). Higher doses of ≥ 9 mg/kg do
not result in further performance enhancement (21), and may even impair
performance due to various side effects (i.e. tachycardia, anxiety, dizziness, nausea)
(15, 23, 51). The pharmokinetics of caffeine is predominantly regulated by hepatic
cytochrome P450 (CYP1A2), the enzyme responsible for metabolizing the majority
of caffeine (18, 39, 46, 47, 58, 65). Therefore, different concentration/activity levels
of CYP1A2 represents a major source of variability in the pharmacokinetics of
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caffeine (64), and consequently the dose-response. The enzyme-saturating dose of
caffeine has been shown to be 6 mg/kg (39), suggesting that this dosage reaches the
upper limit of hepatic caffeine metabolism, which is in line with the aforementioned
dose-performance response relationship.
CYP1A2 is involved in the biotransformation of drugs such as caffeine, along with
being involved in the bioactivation of pro-carcinogens such as estradiol (33).
Demethylation is the first step to caffeine metabolism (31). The three
dimethylxanthine metabolites can be measured in plasma as done in timeconcentration studies (1, 3, 31, 34, 39, 53). Of the three dimethylxanthine
metabolites, paraxanthine (1-7 dimethylxanthine) is more abundant than
theobromine (3,7-dimethylxanthine) and theophylline (1-3-dimethylxanthine)(31,
37); approximately 70-80% of caffeine is converted to paraxanthine (47). Less is
known about paraxanthine kinetics and its potential role in facilitating beneficial
effects of caffeine on exercise performance (11), however, caffeine metabolites have
an even higher affinity for the adenosine receptors (12, 19), thereby plausibly
having an even greater effect on performance than caffeine itself. This indicates that
the rate of caffeine metabolism and consequential metabolite levels could be an
important factor in the ergogenic properties of caffeine. Previous evidence
observing the influence of genotype on caffeine metabolism suggests caffeine affect
those who have faster caffeine metabolism to a greater degree within cycling
performance, which was thought to be due to higher levels caffeine metabolites
(63). This was thought to be due to caffeine metabolites. Indeed, several studies
have reported that specific variations of the CYP1A2 enzyme that impact enzyme
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levels are linked to caffeine-related performance and health outcomes (22, 25, 27,
43, 63).
Directly relevant to the rationale for the current project is that the vast majority of
what is known about the impact on caffeine on performance and physiology has
been derived from males (6, 11, 14, 20, 23, 35, 40, 54, 61, 63). Moreover, the little
that is known about females in this context suggests that there may be sex specific
responses to caffeine intake (10, 20, 36, 38). The rate of caffeine metabolism is not
only sensitive to genetic variations of the enzyme, but also biological sex (6, 31);
specifically, female sex hormones, estrogen and estradiol (1, 3, 18, 24, 48). There is
an evident trend for higher plasma caffeine and lower plasma paraxanthine
concentrations in women compared to men, suggesting that women metabolize
caffeine slower than men (7). Women with higher estrogen levels, [such as oral
contraceptive steroid (OCS) users, females in the luteal phase, or pregnant], have
been found to have decreased CYP1A2 activity and decreased caffeine clearance (3,
34, 48). Despite the varying clearance rates across the menstrual cycle, currently
nothing is known about whether or not this impacts the performance response to
caffeine intake. Therefore, one of the primary aims of this study was to test the
hypothesis that there will be a magnified effect of caffeine on performance in the
follicular phase compared to the luteal phase.
The use of hormonal contraceptives is another condition when estrogen levels are
elevated, (56), possibly effecting the ergogenic effect of caffeine through dampening
the rate of caffeine metabolism. OCS’s can diminish elimination kinetics of several
drugs, including caffeine (53). OCS’s containing ethinyl-estradiol/estradiol/estrogen
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are commonly used by young females as birth control and as treatment for female
athlete triad to prevent bone loss (52), and to treat menstrual disturbances (32, 52).
Chronic OCS use has been previously associated with impaired metabolism of
caffeine (1, 3, 46, 49, 53, 59). There is evidence of delayed caffeine clearance in as
little as the first two weeks of starting OCS use (53). Caffeine half-life was
significantly prolonged (94% longer) in women on OCS as compare to nonusers
(46). A 3-5.5 hour half-life of caffeine is common, however women on OCS’s may
experience increased half-life to approximately 10 hours (7, 34). It is commonly
reported that OCS’s inhibit CYP1A2 activity (1, 3, 26, 49, 50, 59). Whether the
mechanism of CYP1A2 inhibition by estradiol is due to competition or downregulation of enzyme synthesis is unclear (8, 48). OCS’s appear to modify the
metabolism of caffeine by reducing the formation of paraxanthine, which is the
primary pathway of caffeine metabolism, possibly limiting its physiological effects
(50).
The rate at which caffeine is absorbed by the gastrointestinal tract and reaches peak
concentrations in the blood (≈ 60 minutes) is similar for OCS users and non-users
(1, 39, 46). This finding indicates that absorption of caffeine and availability of
plasma caffeine is not altered by OCS use, solely the breakdown of caffeine into its
metabolites is affected. Regardless of the implicit compounding effects of OCS use
on caffeine metabolism, there is no current evidence of the interactive effect OCS use
has on the ergogenic effect of caffeine. Therefore, the second aim of this project is to
test the influence of OCS use on the performance response to caffeine
supplementation compared to non-OCS users.
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Significance:
Despite good evidence that caffeine enhances performance, data among female
participants is sparse. Menstrual status is acknowledged as a contaminate of
caffeine metabolism, but is avoided within performance studies as females are
compared within the same phase, often the early follicular phase (10, 56). Moreover,
the effect that oral contraceptives have on caffeine metabolism has led to the
exclusion of oral contraceptive users in studies examining the effects that caffeine
and caffeine metabolism have on performance. To our knowledge, nothing is known
about how oral contraceptive use may influence the ergogenic effect of caffeine. The
purpose of this study is to determine the effect of oral contraceptive use on caffeine
metabolism and performance following caffeine consumption. Additionally, this
study will yield further insight to the factors that can effect performance
improvement in regards to caffeine ingestion including oral contraceptives and
caffeine metabolism.
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Aims and Hypotheses:
Aim 1: To determine if the phase of the menstrual cycle mediates the effects of
caffeine supplementation on 3k cycling performance time.
Hypothesis 1: Caffeine will elicit a greater improvement in cycling performance time
during the follicular phase compare to the luteal phase.
Aim 2: To determine if oral contraceptive steroid use mediates the effects of caffeine
consumption on 3k cycling performance times.
Hypothesis 2: Caffeine will elicit a greater improvement in cycling performance time
in non-oral contraceptive users compared to the oral contraceptive users.
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Chapter Two
Methodology
Subjects
Thirty recreationally trained female cyclists from James Madison University
and the greater Harrisonburg/ Rockingham County area will be included in this
study. Inclusion criteria include: female, 18-35 years of age, non-smokers, cycle ≥ 30
minutes at least two days a week, and VO2max ≥ 40 ml/kg/min. Further, subjects
must be eumenhorreic with menstrual cycle length between 21-35 days over the
past 6 months. Subjects who are not on any form of contraception will be assigned
to the control group (n=15), and the subjects on monophasic or tri-phasic oral
contraceptives will be assigned to the OCS user group (n=15). In the OCS user group,
subjects will limited to monophasic oral contraceptives or tri-phasic oral
contraceptives containing ethinyl estradiol and levonorgesterel for at least 6 months
(9). Subjects will be fully informed about the experimental procedures and possible
risks before given written informed consent. Informed consent includes information
of the experimental procedures and risks prior to participation. James Madison
University Institutional Review Board approved this study.
Experimental Design
Subjects will report to the laboratory for two familiarization trials and four
experimental trials. Two experimental trials (1 placebo and 1 caffeine) will be
conducted during the luteal phase and two experimental trials (1 placebo and 1
caffeine) will be performed in the follicular phase of the menstrual cycle. The
follicular phase trials will be performed from days 7 to 13 of the menstrual cycle,
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and the luteal phase trials will be performed from days 18 to 24. Each treatment
trial will be performed in the morning between 6:00am and 10:00am. Trials will be
separated by at least 48 hours.
Preliminary Testing
Following height and body mass measurements, VO2max will be assessed
during an incremental test on a bicycle ergometer (Velotron™ cycle ergometer,
Racermate, Inc. Seattle, WA, USA). Workload will begin at 50 W and will be
increased in 25 W increments every minute until volitional fatigue, or pedaling rate
drops below 50 rpm for >10 seconds. Breath samples will be collected and oxygen
consumption will be analyzed with a Moxus® Modular Metabolic System (AEI
Technologies, Pittsburgh, PA, USA). VO2max will be determined as the highest 30
second mean oxygen uptake value.
Supplementation
In a crossover, double-blind design, subjects will be provided caffeine
treatment or placebo. Anhydrous caffeine at 6mg/kg body weight will be measured
into opaque gelatin capsules. For placebo pills, gluten-free rice flour will be put into
opaque gelatin capsules. Supplementation will be ingested with water, 60 minutes
prior to the performance trial.
Familiarization Trials
Two familiarization trials will be completed on a Velotron™ cycle ergometer
before each subjects begins experimental trials. A 5-min warm-up will be performed
before all 3-km time-trials. Subjects will be instructed to approach the time trial as a
competition, emphasizing the importance to perform each trial as a race and put
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forth 100% effort. All trials will be completed without verbal feedback and only
elapsed distance will be displayed. The familiarization trial protocol will be
identical to the performance trials with the exception of caffeine/placebo
supplementation.
Performance Trials
Subjects warmed up on a treadmill for 5 minutes at 3.5 mph, followed by the
3k-time trial on a Velotron cycle ergometer. Performance will be recorded in time to
complete and average watts for the 3-km time trial.
Dietary and Exercise Control
Subjects will complete 24-hour food logs and be instructed to replicate their
diet for 24 hours prior to each subsequent trial. Subjects will be asked to refrain
from any food or drink (besides water) for four hours before and from caffeine and
alcohol for 12 hours before each trial. The OCS user group will be required to
authenticate intake of their respective oral contraceptive within the past 24 hours.
In addition, 48-hour physical activity logs will be completed prior to each trial, and
will be instructed to maintain consistent exercise habits between trials. Subjects will
be asked to refrain from any vigorous physical activity 12 hours prior to each trial.
Statistical Analysis
Magnitude-based inferences about the data will be derived using methods
described by Hopkins and colleagues (29). The smallest worthwhile change in
performance was defined as 0.3 × the within-subject variability of select groups of
elite cyclists across repeated time trials (CV = 1.3% for time and estimated 3.25%
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for power), which translated to a difference in mean power output of 1% or 1.7
watts and 0.4% or 1.4 seconds in the current project (45).
A published spreadsheet by Hopkins (28) will then be used to determine the
likelihoods of the true treatment effect of the population reaching the substantial
change threshold (0.2 x CV); these will be classified as <1% = almost certainly no
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely,
95-99% = very likely, and >99% = almost certain. Clinical inference criteria were
used to classify the effects of treatment on performance. Specifically, if the percent
chance of the effect reaching the substantial change threshold was <25% and the
effect was clear, it was classified as “trivial.” If the percent chance of the effect
reaching the substantial change threshold for benefit exceeded 25% but the chance
for harm was >0.5% the effect was classified as unclear. An exception to the 0.5%
chance of harm criterion was made if the benefit/harm odds ratio was >66, in which
case the effect was interpreted as clear and an inference was assigned.
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Chapter Three
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ABSTRACT
PURPOSE: There is evidence that female sex hormones impact caffeine metabolism,
with decreased CYP1A2 activity and diminished caffeine clearance in women with
higher estrogen levels. Therefore, the objectives of this project were to determine
the effects of oral contraceptives and menstrual cycle on the benefits of caffeine
supplementation for cycling performance. METHODS: Sixteen recreationally trained
female cyclists, oral contraceptive steroid (OCS) users (n=8, age = 21.4 ±1.4 years,
height = 168.4 ± 3.6 cm, weight = 63.6 ± 7.2 kg, VO2max = 48.0 ± 4.0 mlkg-1min-1)
and non-users (n=8, age = 20.9 ± 2.1 years, height = 161.0 ± 7.7 cm, weight = 59.5 ±
9.2 kg, VO2max = 50.9 ± 7.8 mlkg-1min-1), completed four separate computersimulated 3-km cycling time trials (TT). Subjects ingested either 6mg/kg of caffeine
or a placebo capsule one hour prior to each trial. Magnitude based inferences were
used to evaluate treatment effects. RESULTS: Caffeine enhanced 3-km TT
performance (compared to placebo) in early (‘possibly’) and late (‘very likely’)
phases of the menstrual cycle for OCS users by 1.6 ± 2.1% and 2.7 ± 1.4%
respectively. Likewise, caffeine enhanced 3-km TT performance in early and late
(‘likely’) phases of the menstrual cycle for non-users by 2.6 ± 2.3% and 2.1 ± 2.2%.
All other comparisons for OCS users and non-users were ‘unclear’. CONCLUSIONS:
Caffeine supplementation improved 3-km TT finishing time and average power
output in follicular and luteal phases of the menstrual cycle, with unclear effects
between the phases for both OCS users and non-users. This indicates that menstrual
status is not a significant source of variability on the ergogenic effect of caffeine
supplementation on cycling performance.
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INTRODUCTION
Caffeine is commonly consumed for its stimulating effects on the central
nervous system and ability to improve physical performance (6). There is good
evidence that caffeine supplementation can enhance physical performance ranging
from peak strength to prolonged endurance performance (~150 minutes)(4–6, 11,
16, 21, 23, 55, 57, 61, 62), with optimal dosing falling somewhere between 3 and 6
mg of caffeine per kilogram of body mass (14, 21, 23, 57).
Caffeine metabolism is predominantly regulated by hepatic cytochrome P450
(CYP1A2), the enzyme responsible for metabolizing the majority of caffeine (18, 39,
46, 47, 58, 65). Therefore, different concentrations/activity levels of CYP1A2
represents a major source of variability in the pharmacokinetics of caffeine (64).
Demethylation is the first step to caffeine metabolism, which is mostly metabolized
to form paraxanthine (31). Less is known about paraxanthine kinetics and its
potential role in facilitating beneficial effects of caffeine on exercise performance
(11). However, caffeine metabolites have an even higher affinity for the adenosine
receptors, which stimulate the central nervous system (12, 19), thereby plausibly
having an even greater effect on performance than caffeine itself.
The rate of caffeine metabolism is not only sensitive to genetic variations of the
enzyme, but also biological sex (6, 31). Specifically, female sex hormones, estrogen
and estradiol influence caffeine levels following supplementation (1, 3, 18, 24, 48).
There is an evident trend for higher plasma caffeine and lower plasma paraxanthine
concentrations in women compared to men, suggesting that women metabolize
caffeine slower than men (7). Moreover, women with higher estrogen levels, [such
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as oral contraceptive steroid (OCS) users, females in the luteal phase, or during
pregnancy], have been found to have lower CYP1A2 activity and decreased caffeine
clearance (3, 34, 48). Whether the mechanism of CYP1A2 inhibition by estrogen is
due to competition or down-regulation of enzyme synthesis is unclear (8, 48).
Despite the varying clearance rates across the menstrual cycle, currently nothing is
known about whether or not this impacts the performance response to caffeine
intake. Therefore, one of the primary aims of this study was to test the hypothesis
that there will be a magnified effect of caffeine on performance in the follicular
phase compared to the luteal phase.
In addition to menstrual phase, estrogen levels are also elevated with certain
types of oral contraceptives, (56), conceivably altering the ergogenic effect of
caffeine via an attenuated rate of caffeine metabolism. Chronic OCS use has been
previously associated with impaired metabolism of caffeine (1, 3, 46, 49, 53, 59),
and it is commonly reported that OCS’s inhibit CYP1A2 activity (1, 3, 26, 49, 50, 59).
OCS’s appear to modify the metabolism of caffeine by reducing the formation of
paraxanthine, which is the primary pathway of caffeine metabolism, possibly
limiting its physiological effects (50). There is no current evidence of the interactive
effect OCS use has on the ergogenic effect of caffeine. Therefore, the second aim of
this project is to test the influence of OCS use on the performance response to
caffeine supplementation compared to non-OCS users.
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METHODOLOGY
Subjects
Twenty-eight healthy, recreationally trained female cyclists (15 OCS users,
13 non-users) from James Madison University and the greater Harrisonburg/
Rockingham County area volunteered for the study. However, seven OCS users and
five non-users withdrew from the study due to injuries, Lyme disease diagnosis,
switching birth control prescription, seasonal flu, vasovagal syncope, or scheduling
difficulties.
Inclusion criteria included: female, 18-35 years of age, non-smokers, cycle ≥
30 minutes at least two days a week, and VO2max ≥ 40.0 mlkg-1min-1. Further,
subjects were required to be eumenhorreic with menstrual cycle length between
21-35 days over the past 6 months. Descriptive data are shown in Table 1. Subjects
who were not on any form of contraception were assigned to the control group
(n=8), and the subjects on monophasic or tri-phasic oral contraceptives were
assigned to the OCS user group (n=8). In the OCS user group, subjects were limited
to monophasic oral contraceptives or tri-phasic oral contraceptives containing
levonorgesterel and ethinyl-estradiol for at least 6 months to ensure consistent
levels of estradiol (9).
Subjects were fully informed about the experimental procedures and
possible risks before given written informed consent. Informed consent included
information of the experimental procedures and risks prior to participation. James
Madison University Institutional Review Board approved this study.
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Experimental Design
Subjects reported to the laboratory for two familiarization trials and four
experimental trials. Two experimental trials (1 placebo and 1 caffeine) were
conducted during the follicular phase and two experimental trials (1 placebo and 1
caffeine) were performed in the luteal phase of the menstrual cycle. Experimental
trials during the follicular phase were performed from days 7 to 13 of the menstrual
cycle, and the luteal phase trials were performed from days 18 to 24. Menstrual
status was not verified by secondary measures (i.e. estrogen levels, body
temperature, etc.). As such, the presumed follicular and luteal phases will be
referred to as ‘early’ and ‘late’ phases, respectively.
Preliminary Testing
Following height and body mass measurements, maximal oxygen
consumption (VO2max) was assessed during an incremental test on a bicycle
ergometer (Velotron™ cycle ergometer, Racermate, Inc. Seattle, WA, USA). Workload
started at 50 W and was increased in 25 W increments every minute until volitional
fatigue, or pedaling rate dropped below 50 rpm for >10 seconds. Breath samples
were collected and oxygen consumption (VO2) was analyzed with a Moxus® Modular
Metabolic System (AEI Technologies, Pittsburgh, PA, USA). VO2max was determined
as the highest 30 second mean oxygen uptake value.
Supplementation
In a crossover, double-blind design, subjects were provided caffeine
treatment or placebo. Anhydrous caffeine (6 mg/kg body mass) was measured into
opaque gelatin capsules. For placebo pills, gluten-free rice flour was put into opaque
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gelatin capsules. Supplementation was ingested with water 60 minutes prior to the
performance trial.
Familiarization Trials
Prior to the experimental trials, two separate familiarization trials were
completed on a Velotron™ cycle ergometer. A 5-min self-selected warm-up was
performed before all 3-km time-trials. Subjects were instructed to approach the
time trial as a competition, emphasizing the importance to perform each trial as a
race. All trials were completed without verbal feedback and only elapsed distance
was displayed. The familiarization trial protocol was identical to the performance
trials with the exception of caffeine/placebo supplementation.
Performance Trials
The subjects performed a 5-min warm-up, followed by a computer-simulated
3-km time trial on the Velotron cycle ergometer. Average power output during the
time trial and finishing times were recorded and used as the performance measures.
Dietary and Exercise Control
Subjects completed 24-hour food logs and were instructed to replicate their
diet for 24 hours prior to each subsequent trial. Subjects were asked to refrain from
any food or drink (besides water) for four hours before and from caffeine and
alcohol for 12 hours before each trial. The OCS user group was required to
authenticate intake of their respective oral contraceptive within the past 24 hours.
In addition, 48-hour physical activity logs were completed prior to each trial, and
subjects were instructed to maintain consistent exercise habits between trials. In
addition, subjects were asked to refrain from any vigorous physical activity 12
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hours prior to each trial. Each treatment trial was performed in the morning
between 6:00am and 10:00am. Trials were separated by at least 48 hours.
Statistical Analysis
Magnitude-based inferences were derived using methods described by
Hopkins and colleagues (29). The smallest worthwhile change in performance was
defined as 0.3 × the within-subject variability of select groups of elite cyclists across
repeated time trials (CV = 1.3% for time and estimated 3.25% for power), which
translated to a difference in mean power output of 1% or 1.7 watts and 0.4% or 1.4
seconds in the current project (45).
A published spreadsheet by Hopkins (28) was used to determine the
likelihoods of the true treatment effect of the population reaching the substantial
change threshold; these were classified as <1% = almost certainly no chance, 1-5% =
very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely, 95-99% = very
likely, and >99% = almost certain. If the percent chance of the effect reaching the
substantial change threshold was <25% and the effect was clear, it was classified as
‘trivial’ effect. If 90% confidence intervals included values that exceeded the
substantial change threshold for both a positive and negative effect, effects were
classified as unclear (>5% chance of reaching the substantial threshold for both a
positive and negative effect).
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Results
3-km Time Trial Performance
In general, caffeine enhanced 3-km TT performance (compared to placebo) in
OCS users and non-users in both menstrual phases. 3-km TT performance data
(finishing time) are reported in Figure 1 and Table 2. In addition, the 3-km TT
power output data (average wattage) are reported in Table 2.
For the non-user group, caffeine ‘likely’ improved performance time by 2.6 ±
2.3% during the early phase and by 2.1 ± 2.2% in the late phase. Likewise, caffeine
‘likely’ increased power output by 6.7 ± 6.1% in the early phase and ‘very likely’
increased power output by 6.7 ± 4.8% in the late phase. It was ‘unclear’ whether
there were differences in the magnitude of benefit from caffeine between the early
and late phases for finishing time and average wattage.
Similarly for the OCS users, caffeine ‘possibly’ improved performance by 1.6
± 2.1% during the early phase and ‘very likely’ improved performance by 2.7 ± 1.4%
during the late phase. While, power output was ‘likely’ increased by 4.7 ± 5.6% in
the early phase, and was ‘very likely’ increased by 7.2 ± 3.7% in the late phase.
When comparing finishing time for non-users and OCS users by average of
both phases, the outcome is ‘unclear’ to whether non-users or OCS users benefitted
more altogether.
Discussion
The purpose of the current study was to investigate how two distinct phases
of the menstrual cycle and the use of oral contraceptives influenced the ergogenic
effects of caffeine on 3-km cycling performance. The major finding was that caffeine
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improved 3-km time trial performance for female cyclists during both the early and
late phases of the menstrual cycle, with no clear difference between the early or late
phase of the menstrual cycle. Further, oral contraceptive status (users vs. nonusers) did not appear to systematically influence the ergogenic effect of caffeine
supplementation. The collective data suggest that menstrual status is not a
significant source of variation in the performance response to caffeine
supplementation.
While not measured in the current study, the concentrations of endogenous
female sex hormones vary considerably during the menstrual cycle, with estradiol
concentration in serum rising from 10-30 pg/ml in the follicular phase to 80-200
pg/ml during the luteal phase (65). Given the prior evidence of slowed caffeine
metabolism with higher levels of estrogen (3, 34, 48), we suspected that high
estrogen levels associated with the late menstrual phase (luteal) would slow
caffeine metabolism. As a result, we hypothesized that non-OCS users would
experience higher caffeine: metabolite levels following supplementation in the late,
versus early phase, thus leading to a greater caffeine benefit. To our knowledge, this
is the first study to investigate the menstrual phase as a possible source of the
variation in the ergogenic effect of caffeine supplementation. Therefore it is not
possible to compare to previous findings. However, the absence of a systematic
difference in the performance benefit of caffeine between menstrual phases
observed here is indirectly supported by prior studies indicating the males and
females benefit similarly to caffeine ingestion (2, 10, 20). It may be that alterations
in hepatic P-450 enzyme activity between phases of the menstrual cycle are not
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physiologically relevant, as shown in drug therapy (65), Also noted by a metaanalysis of the effect of the menstrual cycle on metabolism during exercise, a
limitation to this study is the participation following an overnight fast, as a positive
nutritional state may lessen the impact of ovarian hormones on metabolism during
exercise (41). Thus, the effect of estrogen on CYP1A2 enzyme activity may not be
enough to influence the ergogenic effect of caffeine despite the fact that we tested
subjects under dietary conditions that should have magnified the impact of
estrogen. Estrogen may have less of an effect following usual dietary intake.
Using the same logic outlined above, because we suspected that OCS users
would have had higher estrogen levels than non-users, we therefore hypothesized
OCS users would have slowed caffeine metabolism, thus lower caffeine: metabolite
ratio leading to less benefit of caffeine compared to non-users. Again, in contrast to
our hypothesis, there was no clear difference in the performance response to
caffeine between OCS users and non-users. Therefore, the difference of estrogen
levels in modern OCS may not compromise caffeine metabolism to a degree
influences the ergogenic effect of caffeine. It is important to note that the outcome
was ‘unclear’, which does not indicate consistent/similar responses between
groups, but rather marked variability in the responses to caffeine. This suggests that
more data needs to be gathered before drawing firm conclusions about potential
differences.
It is well known that there is significant individual variability in the
performance response to caffeine. Our laboratory, and others, have suggested that
this variability may be related to differences in the rate of caffeine metabolism and
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absorption between individuals (42, 44, 63). There is evidence that peak blood
caffeine levels occur one hour after ingestion (4), and that these levels are similar
for both OCS users and non-users (46). Thus we know absorption of caffeine is
similar in OCS users and non-users, but rates of metabolism are highly variable.
Therefore, we speculate that the difference in ergogenic effect of caffeine between
these two groups would be greater beyond one hour post-ingestion, as the half-life
of caffeine is prolonged in OCS users (46). Future research should consider
evaluating performance more than one-hour post caffeine ingestion to establish the
effect of caffeine metabolism rate, or caffeine and metabolite concentrations, on
ergogenic effect of caffeine.
One major limitation of the current study is the presumption of different
estrogen levels between the early and late phases. Although there is strong evidence
of diminished caffeine metabolism with high levels of estradiol (53), we have no
measure to determine caffeine elimination kinetics within our sample. In order to
evaluate the influence of the menstrual cycle, it was essential to determine
menstrual phases to keep hormone levels consistent within an investigation, which
was done by examining women outside of the days of menses and the days of
ovulation (where spikes in other female hormones, such as progesterone and
follicular-stimulating hormone occur) (30, 56).
The primary strength of this project was the concomitant investigation of
oral contraceptive status and menstrual phase, two conditions that presumably
impact estrogen levels, on the benefit that caffeine has on simulated performance.
Unfortunately the outcomes from this investigation are considerably weakened by
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the absence of blood estrogen measurements. Therefore, we cannot definitely
conclude that estrogen levels, per se, do not alter the performance response to
caffeine. Altogether, the results from this investigation indicate that females derive
performance benefits from caffeine irrespective of menstrual phase and despite use
of OCS, however, the magnitude to which benefits occur under these conditions are
unclear.
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Table 1.0 Descriptive Data
Total (n=16)

Non-Users (n=8)

OCS Users (n=8)

Height (cm)

164.7 ± 6.9

161.0 ± 7.7

168.4 ± 3.6

Weight (kg)

61.2 ± 8.6

58.8 ± 9.7

63.6 ± 7.2

Age (yrs)

21.1 ± 1.8

20.6 ± 2.1

21.4 ± 1.4

VO2max (ml/kg/min)

49.7 ± 6.5

51.3 ± 8.2

48.0 ± 4.0

Cycling (hrs/week)

3.1 ± 1.9

3.8 ± 2.0

2.4 ± 1.7

Caffeine (mg/week)

601.1 ± 494.9

623.4 ± 551.1

578.9 ± 469.0

Descriptive data reported as mean, SD
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Table 2. 3-km Performance Time and Power Output Data
Between-Condition

Mean ± SD

Within-Condition Differences; ∆PLA vs. CAF

Differences ∆Early vs. Late

Mean, ± 90%CI (raw)

Mean, ± 90%CI (raw)

% Likelihoods (+/triv/-), Inference

% Likelihoods (+/triv/-),
Inference
1&3, vs.
1 vs. 3 (Non-

Variable

Condition

PLA

CAF

PLA vs. CAF

Users: Early

2&4 (Users
vs. Non

vs. Late)

Users)

(1) Non-

358.9 ± 43.1

349.9 ± 44.2

2.6 ± 2.3, % likelihoods (2, 4, 94) likely

Users Early

(167.1 ± 51.6)

(178.4 ± 52.5)

beneficial

Time in

(2) Users

356.8 ± 28.3

351.0 ± 28.4

1.6 ± 2.1, % likelihoods (3, 26, 71) possibly

0.5 ± 3.0, %

0.1 ± 1.9, %

seconds

Early

(162.3 ± 28.5)

(170.1 ± 31.8)

beneficial

likelihoods

likelihoods

(Power

(3) Non-

356.3 ± 38.2

348.2 ± 31.5

2.1 ± 2.2, % likelihoods (3, 6, 91) likely

(30.1,17.6,

(32.1,29,39)

Output in

Users Late

(167.6 ± 47.9)

(177.0 ± 41.4)

beneficial

52.3), unclear

Unclear

Watts)

(4) Users

354.7 ± 22.9

345.0 ± 21.3

2.7 ± 1.4, % likelihoods (0, 2, 98) very likely

Late

(164.1 ± 24.5)

(176.0 ± 27.0)

beneficial

3-km TT

Values for Placebo (PLA) and Caffeine (CAF) reported as Mean ± SD. Comparison values reported Mean±90% CI for differences between change
scores (i.e. Early vs. Late), % likelihoods of positive effect/trivial effect/negative effect and semantic inferences.
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3-km Time Trial Performance (seconds)

380.0
375.0

b

370.0

c

365.0

b

360.0

a

355.0

Placebo

350.0

Caffeine

345.0
340.0
335.0
330.0
Non-User
Early

OCS User

Non-User

OCS Users
Late

Figure 1 Average (mean ± SE) 3-km Time Trial performance for the caffeine and placebo
treatments for non-oral contraceptive users and oral contraceptive users during the early
and late phases.

Effects of Caffeine during 3-km Time Trial performance in seconds: Bars depict mean time
in seconds (± SE). (a) ‘Very likely’ improvement vs. placebo. (b) ‘Likely’ improvement vs.
placebo. (c) ‘Possible’ improvement vs. placebo.
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Appendix A
James Madison University
Department of Kinesiology
Consent for Investigative Procedure

I, ______________________, hereby agree on _____________ (date) to participate in the research
project conducted by Nicholas D. Luden, Ph.D., and Annette Lemanski from James Madison
University titled The Effect of Oral Contraceptives on Caffeine Metabolism and Performance.
The purpose of this study is to determine the impact of oral contraceptives on caffeine
metabolism and cycling performance.
Subject Responsibility
I understand that I will undergo the following testing in the study:
This study consists of seven separate exercise tests performed on a stationary bike
(cardiovascular fitness test, one familiarization test, and four 3km time trial tests). All testing
will occur in Godwin Hall, room 209, on the campus of James Madison University. You will
also be asked about lifestyle behaviors such as smoking and physical activity and oral
contraceptive use and duration of use. The total time commitment is estimated to be less
than 6 hours over the course of 8 weeks.
Pre-testing 1 (60 min):
After completing this consent form and the health history screening, if you meet the inclusion
criteria for the study, researchers will measure your height and body weight.
You will then be asked to perform a maximal cardiovascular fitness test to determine peak
oxygen consumption (VO2max). You will be asked to ride a stationary bike at an initial
workload that is ‘fairly easy’. The workload will then be increased every two minutes until
exhaustion is reached, determined by either: 1) your request to stop due to fatigue, or 2)
inability to maintain a cadence of ≥50 revolutions per minute. You will be verbally
encouraged to continue to obtain an accurate measurement of VO2max. To access oxygen
consumption, you will need to breathe through a mouthpiece/breathing apparatus which
collects expired air throughout the test (10-15 minutes).
Familiarization Trials (n =2; 30 minutes):
On one occasion, you will be asked to perform a 3-km cycling practice trial on a stationary
bike. You will warm-up with a 5-minute treadmill test at 3.5 mph, followed by the stationary
bicycle 3-km time trial. You will be encouraged to treat the time trial like a competition.
Experimental Trials (n=4; 90 minutes each):
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You will report to the laboratory 60 minutes prior to exercise testing. You will rest in a seated
position for 5 minutes, after which a blood sample will be obtained for measurement of
caffeine levels (one of the samples will also be used to extract DNA for genotyping).
Immediately following the blood draw, you will ingest either placebo or caffeine capsules,
after which you will wait for ~60 minutes in the laboratory until exercise testing.
Immediately prior to exercise testing, a second blood sample will be obtained for the
measurement of caffeine levels. Following the blood draw, you will complete the 3-km time
trial described above.
Supplementation Protocol:
No supplementation will be given during the familiarization trial. You will be randomly
assigned a treatment order. Treatments will be: 1. Placebo capsule containing flour
administered 1hr prior to exercise between 6-10am 2. Caffeine capsule containing 6
mg/kg bodyweight caffeine administered 1hr prior to exercise between 6-10am.
DNA Sampling:
We will extract a sample of your DNA from one of your blood samples to determine the type
of enzyme that you have to breakdown caffeine. DNA and blood samples will be stored in our
laboratory freezer indefinitely to allow us to conduct follow-up studies in the event that new
discoveries are made related to DNA and caffeine metabolism. Your sample will be destroyed
immediately upon request. Your sample will be coded so that nobody except the primary
investigators can identify which sample is yours. The DNA testing will involve determining
sequences of DNA for specific genes that are related to caffeine metabolism. We will not use
this DNA for any other purpose. The results of this genetic testing will only be available to
the primary investigator and you. These results will not be made public and will be stored in
a locked file cabinet.
Risks/Benefits
Cardiovascular Exercise (3-km Time Trial and VO2max test)
According to the American College of Sports Medicine’s Guidelines for Exercise Testing and
Prescription, the risk associated with heavy exercise for individuals categorized as “low risk”
is very minimal, and physician supervision is not necessary. The conditions that the exercise
sessions are to take place are likely safer than the typical exercise environments of the
subjects. If you do not meet ACSM criteria for “low risk”, you will not be allowed to participate
in the study. In the unlikely event of cardiac or other complications during exercise, an
emergency plan is in place. This includes immediate access to a phone to call emergency
personnel. In addition, at least one of the listed investigators will be present during the
exercise sessions, and all are CPR certified.

Blood Sampling
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The risks of blood sampling using venipuncture include possible mild bruising, and the risk
of transfer of blood-borne pathogens, as well as possible risks of infection or skin irritation.
These risks are considered to be minimal, and all safety precautions for handing blood
samples will be followed according to OSHA protocols, including: investigators will wear
latex gloves at all times during blood sampling and testing. A sharps container lined with a
biohazard bag will be used for all sharp objects involved in the blood sampling; all other
materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in a separate
waste disposal unit lined with a biohazard bag. All investigators who will be involved in
blood draws (and handling of blood) have been trained in these phlebotomy techniques, and
completed JMU blood-borne pathogen training. The total amount of blood obtained during
this study is approximately 25 ml. For reference, this amount is ~ 6% of a can of soda, or 5%
of the amount given when donating blood in a single session (approximately 1 pint, or 473
ml).
Caffeine Ingestion
The risks and side effects associated with caffeine supplementation include: rapid heart rate,
elevated blood pressure, headache, nausea, vomiting, restlessness, agitation, and anxiety.
Performance incentive:
The top 10 performers will be entered into a drawing to win a $150 and $75.
Confidentiality
The results of this research will be presented at conferences and published in exercise
science journals. The results of this project will be coded in such a way that your identity
will not be attached to the final form of this study. The researcher retains the right to use
and publish non-identifiable data. However, you can ask that your data be removed from the
study at any point prior to presentation and publication. While individual responses are
confidential, aggregate data will be presented representing averages or generalizations
about the responses as a whole. All data will be stored in a secure location accessible only
to the researcher. Final aggregate results will be made available to you upon request.
Participation & Withdrawal
Your participation is entirely voluntary. You are free to choose not to participate. Should
you choose to participate, you can withdraw at any time without consequences of any kind.
Your right to withdraw includes the right to request that your DNA and blood samples be
discarded at any time. You should be aware that the DNA sample is subject to court
subpoena. To dispose of your samples, your samples will be rinsed down a chemical drain in
our laboratory or will be disposed of in a biohazard container. Again, your sample will not
be identifiable without the coding document that will be locked away in a filing cabinet.

Questions
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You may have questions or concerns during the time of your participation in this study, or
after its completion. If you have any questions about the study, contact Annette Lemanski,
lemansam@dukes.jmu.edu. Or by phone (715) 340- 4423

Giving of Consent
I have read this consent form and I understand what is being requested of me as a participant
in this study. I freely consent to participate. I have been given satisfactory answers to my
questions. The investigator provided me with a copy of this form. I certify that I am at least
18 years of age.

Name of Participant (Printed)

Name of Researcher(s) (Printed)

Name of Participant (Signed)

Name of Researcher(s) (Signed)

Date

Date

For questions about your rights as a research subject, you may contact the chair of JMU’s
Institutional Review Board (IRB). Dr. David Cockley, (540) 568-2834, cocklede@jmu.edu.

Appendix B

AHA/ACSM Health/Fitness Facility Pre-participation Screening Questionnaire
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Assess your health status by marking all true statements
History
You have had:
a heart attack
heart surgery
cardiac catheterization
coronary angioplasty (PTCA)
pacemaker/implantable cardiac
defibrillator/rhythm disturbance
heart valve disease
heart failure
heart transplantation
congenital heart disease
Symptoms
You experience chest discomfort with exertion
You experience unreasonable breathlessness
You experience dizziness, fainting, or blackouts
You take heart medications

If you marked any of these
statements in this section, consult
your physician or other appropriate
health care provider before
engaging in exercise. You may need
to use a facility with a medically
qualified staff.

Other Health Issues
You have diabetes
You have asthma or other lung disease
You have burning or cramping sensation in your lower
legs when walking short distances
You have musculoskeletal problems that limit your
physical activity
You have concerns about the safety of exercise
You take prescription medication(s)

Cardiovascular risk factors
You are a man older than 45 years
You smoke, or quit smoking within the previous 6 months
Your blood pressure is > 140/90 mmHg
You do not know your blood pressure
You take blood pressure medication
Your blood cholesterol level is > 200 mg/dl
You do not know your cholesterol level
You have a close blood relative who had a heart attack or
heart surgery before age 55 (father or brother) or age 65
(mother or sister)
You are physically inactive (i.e. you get < 30 minutes of
physical activity on at least 3 days of the week)
You are > 20 pounds overweight
None of the above

If you marked two or more of the
statements in this section, you
should consult your physician or
other appropriate health care
provider before engaging in
exercise. You might benefit from
using a facility with a
professionally qualified exercise
staff to guide your exercise
program.

You should be able to exercise safely
without consulting your physician
or other appropriate health care
provider in a self-guided program or
almost any facility that meets your
exercise program needs.
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Appendix C
Subject Prescreening Information and Caffeine Habits
Age: ______years
Height: __________

Weight: __________

Typical Exercise Habits over the past 3 months
Average number of days cycling per week: ________
Average number of hours cycling per week: ________
Do you have a muscle or joint injury that precludes you from completing the cycling
protocol?
Allergies:
Are you allergic tor rice flour?
Are you allergic to latex?
Contraceptive use:
Are you currently on any form of contraceptives (including the ring, IUD, etc)?
Are you currently using oral contraceptives?
If yes, what is the brand name of your current medication?
How long have you been using oral contraceptives?
Approximately how long is your menstrual cycle (in days)? Menstrual cycle is day one
of menses to the next day one of menses.
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Caffeine Habits
Please list your approximate weekly intake of the following:
Cups of coffee:
Cups of tea:
Cans (12oz) caffeinated soda:
Servings of chocolate:
Doses of caffeinated pills:
Other caffeinated beverages or supplements not listed
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